February

John Bender, M.D.; Decision and Order (PDF) (February 13, 2026)

Scottsdale Research Institute (PDF) (February 13, 2026)

Siemens Healthcare Diagnostics, Inc. (PDF) (February 13, 2026)

S&B Pharma LLC DBA Norac Pharma (PDF) (February 13, 2026)

Scottsdale Research Institute (PDF) (February 13, 2026)

Final Rule: Registering Emergency Medical Services Agencies Under the Protecting Patient Access to Emergency Medications Act of 2017 (PDF) (February 5, 2026)

S & B Pharma LLC DBA Norac Pharma (PDF) (February 4, 2026)

Sterling Pharma USA LLC (PDF) (February 4, 2026)

Mylan Inc. (PDF) (February 2, 2026)

Promega Corporation (PDF) (February 2, 2026)

Sharp Clinical Services, LLC (PDF) (February 2, 2026)

Medi-Physics Inc. DBA GE Healthcare (PDF) (February 2, 2026)

January 2026

30-Day Notice: Drug Use Statement (PDF) (January 28, 2026)

Allied Medical Products, Inc.; Decision and Order (PDF) (January 27, 2026)

Adam Maass, M.D.; Decision and Order (PDF) (January 27, 2026)

Complete Care Pharmacy, LLC; Decision and Order (PDF) (January 27, 2026)

Maridose LLC (PDF) (January 23, 2026)

Organic Consultants LLC DBA Cascade Chemistry (PDF) (January 23, 2026)

Siegfried USA, LLC (PDF) (January 22, 2026)

Mylan Pharmaceuticals Inc. (PDF) (January 21, 2026)

Notice of Intent: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I (PDF) (January 20, 2026)

Final Rule: Definition of "Cannabimimetic Agents" and Assignment of an Administration Controlled Substances Code Number for All "Cannabimimetic Agents" (PDF) (January 20, 2026)

Siegfried USA, LLC (PDF) (January 16, 2026)

Final Rule: Placement of 4-Fluoroamphetamine in Schedule I (PDF) (January 15, 2026)

Walter Walters, M.D.; Decision and Order (PDF) (January 15, 2026)

Honorata Anna Itaman, N.P.; Decision and Order (PDF) (January 15, 2026)

Pine Pharmacy; Decision and Order (PDF) (January 15, 2026)

Jason Vanshaar, M.D.; Decision and Order (PDF) (January 15, 2026)

Mark Huff, M.D.; Decision and Order (PDF) (January 15, 2026)

Final Order: Placement of N-Pyrrolidino Metonitazene and N-Pyrrolidino Protonitazene in Schedule I (PDF) (January 12, 2026)

Curium US LLC (PDF) (January 8, 2026)

Mylan Technologies Inc. (PDF) (January 8, 2026)

Janssen Pharmaceuticals Inc. (PDF) (January 8, 2026)

AndersonBrecon, Inc. DBA PCI Pharma Services (PDF) (January 8, 2026)

Final Order: Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2026 (PDF) (January 5, 2026)

60-Day Notice: Registration for Controlled Substances Act Data-Use Request (PDF) (January 2, 2026)

December

Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications (PDF) (December 31, 2025)

Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I (PDF) (December 23, 2025)

David Halvorson, M.D.; Decision and Order (PDF) (December 22, 2025)

National Center for Natural Products Research (PDF) (December 22, 2025)

Navinta LLC (PDF) (December 22, 2025)

Myonex LLC (PDF) (December 22, 2025)

IsoSciences, LLC (PDF) (December 22, 2025)

Timothy Balisky, N.P.; Decision and Order (PDF) (December 19, 2025)

Aveva Drug Delivery Systems, Inc. (PDF) (December 19, 2025)

Bright Green Corporation (PDF) (December 19, 2025)

Janssen Pharmaceuticals, Inc. (PDF) (December 19, 2025)

Groff Health Inc. (PDF) (December 19, 2025)

Proposed Rule: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I (PDF) (December 16, 2025)

Extension of Temporary Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I of the Controlled Substances Act (PDF) (December 16, 2025)

Temporary Placement of Bromazolam in Schedule I (PDF) (December 15, 2025)

Proposed Rule: Placement of CUMYL-PEGACLONE in Schedule I (PDF) (December 11, 2025)

Extension of Temporary Placement of MDMB-4en-PINACA in Schedule I of the Controlled Substances Act (PDF) (December 11, 2025)

Extension of Temporary Placement of CUMYL-PEGACLONE in Schedule I of the Controlled Substances Act (PDF) (December 11, 2025)

Latania Akers-White, M.D.; Decision and Order (PDF) (December 4, 2025)

Kinetochem LLC (PDF) (December 3, 2025)

Invizyne Technologies, Inc. (PDF) (December 1, 2025)

Blue Rabbit Veterinary LLC (PDF) (December 1, 2025)

Benuvia Operations, LLC (PDF) (December 1, 2025)

November

Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2026 (PDF) (November 28, 2025)

Groff NA Hemplex LLC (PDF) (November 26, 2025)

Halo Pharmaceutical Inc. (PDF) (November 26, 2025)

Siegfried Grafton, Inc. (PDF) (November 26, 2025)

Caligor Coghlan Pharma Services (PDF) (November 26, 2025)

Noramco (PDF) (November 26, 2025)

NSI Lab Solutions, LLC (PDF) (November 26, 2025)

Irvine Labs, Inc. (PDF) (November 26, 2025)

Noramco (PDF) (November 26, 2025)

Organic Standards Solutions International, LLC (PDF) (November 26, 2025)

Siegfried Grafton, Inc. (PDF) (November 26, 2025)

Eli-Elsohly Laboratories (PDF) (November 26, 2025)

VHG Labs DBA LGC Standards (PDF) (November 26, 2025)

Benuvia Operations, LLC (PDF) (November 26, 2025)

Organix Chemistry Solutions, LLC (PDF) (November 26, 2025)

National Center for Natural Products Research (PDF) (November 26, 2025)

Fisher Clinical Services, Inc. (PDF) (November 26, 2025)

Cayman Chemical Company (PDF) (November 26, 2025)

Irvine Labs Inc. (PDF) (November 26, 2025)

Irvine Labs, Inc. (PDF) (November 26, 2025)

30-Day Notice: DEA Voluntary Wellness Program Healthcare Provider Clearance (PDF) (November 24, 2025)

60-Day Notice: Drug Use Statement (PDF) (November 24, 2025)

30-Day Notice: Report of Mail Order Transactions (PDF) (November 18, 2025)

Final Rule: Placement of 4-Chloromethcathinone in Schedule I (PDF) (November 17, 2025)

October

Tracy Amerson-Rivers, A.P.R.N.; Decision and Order (PDF) (October 30, 2025)

Antony Vanbang, M.D.; Decision and Order (PDF) (October 30, 2025)

Dawn Evert, N.P.; Decision and Order (PDF) (October 30, 2025)

Pharmacy Place, Llc; Decision and Order (PDF) (October 30, 2025)

Lawrence Michael Willis, D.D.S.; Decision and Order (PDF) (October 30, 2025)

Mert Kivanc, D.O.; Decision and Order (PDF) (October 21, 2025)

MCRGC, LLC; Decision and Order (PDF) (October 21, 2025)

Enyibuaku Uzoaga, M.D.; Decision and Order (PDF) (October 21, 2025)

Hil Rizvi, M.D.; Decision and Order (PDF) (October 21, 2025)

Abolghasem Rezaei, M.D.; Decision and Order (PDF) (October 20, 2025)

Ali Elhorr, M.D.; Decision and Order (PDF) (October 20, 2025)

Chantal F. Nouvellon, D.O.; Decision and Order (PDF) (October 20, 2025)

James Orrington, II, D.D.S.; Decision and Order (PDF) (October 20, 2025)

Grace S. Joanita, N.P.; Decision and Order (PDF) (October 17, 2025)

Hovic Pharmacy; Decision and Order (PDF) (October 17, 2025)

Shannon Wagner, D.O.; Decision and Order (PDF) (October 17, 2025)

David S. Pecora, P.A.; Decision and Order (PDF) (October 17, 2025)

Temporary Placement of Ethyleneoxynitazene, Methylenedioxynitazene, 5-Methyl Etodesnitazene, N-Desethyl Etonitazene, N-Desethyl Protonitazene, N,N-Dimethylamino Etonitazene, and N-Pyrrolidino Isotonitazene in Schedule I (PDF) (October 15, 2025)

Final Order: Adjustment to the Aggregate Production Quota for d-Amphetamine (For Sale) and Methylphenidate (For Sale) for 2025 Pursuant to 21 U.S.C. 826(h) (PDF) (October 2, 2025)

Hollywood Medical Rehabilitation Care, Inc.; Decision and Order (PDF) (October 2, 2025)

Cargill, Incorporated (PDF) (October 2, 2025)

Proposed Rule: Designation of P2P Methyl Glycidic Acid as a List I Chemical (PDF) (October 2, 2025)

Proposed Rule: Placement of MDMB-4en-PINACA in Schedule I (PDF) (October 2, 2025)

Final Rule: Requiring Online Submission of Applications for and Renewals of DEA Registration: Technical Correction (PDF) (October 2, 2025)

Final Rule: Specific Listing for 1-boc-4-piperidone, a Currently Controlled List I Chemical (PDF) (October 2, 2025)

Final Rule: Controlled Substances Ordering System (CSOS) Modernization (PDF) (October 2, 2025)